Press release
Apr 15, 2019

Sosei Heptares notes abstracts and posters reporting clinical and preclinical data from studies with immuno-oncology candidate AZD4635, presented by AstraZeneca at AACR 2019, are available

Tokyo, Japan and London, UK, 15 April 2019 – Sosei Group Corporation (“the Company”; TSE: 4565) notes that the abstracts presented by AstraZeneca at the 2019 American Association for Cancer Research (AACR) Annual Meeting (29 March to 3 April 2019) are available at the links below – the presented posters and a summary of key findings have now been added to the Science Center section on our website.


Abstract #CT026: Merchant, MS, et al. Evidence of immune activation in the first-in-human Phase 1a dose escalation study of the adenosine 2a receptor antagonist, AZD4635, in patients with advanced solid tumors


Abstract #LB-192: Barbon, CM, et al. The A2AR antagonist AZD4635 prevents adenosine-mediated immunosuppression of CD103+ dendritic cells


–        ENDS  –